HistoMosaic Detecting KRAS G12V Mutation Across Colorectal Cancer Tissue Slices through in Situ PCR.
HistoMosaic Detecting KRAS G12V Mutation Across Colorectal Cancer Tissue Slices through in Situ PCR.
复制标题
DOI：
10.1021/acs.analchem.5b04460
复制
发表时间：
2016-03-01
影响因子：
7.4
通讯作者：
Kartalov E
中科院分区：
文献类型：
--
作者：
Raub CB;Lee CC;Shibata D;Taylor C;Kartalov E
我们报道了HistoMosaic，一种用于福尔马林固定石蜡包埋组织切片遗传分析的新技术。它结合了微流体区隔化，原位等位基因特异性PCR和荧光显微镜。通过原位检测KRAS G12V突变在结直肠癌组织中实现了原理的实验证明，并在此提出。HistoMosaic提供了在整个组织切片上同时、快速、经济地检测突变的能力，并且没有选择偏差，同时将遗传信息与保存的形态学信息共同注册。因此，HistoMosaic作为一种绘制遗传异质性的工具在基础科学中具有广泛的适用性。它也是一个为肿瘤学靶向治疗构建伴随诊断的平台，以帮助确保为正确的患者提供正确的药物，从而节省医疗资源并改善患者的治疗效果。
We report on HistoMosaic, a novel technique for genetic analysis of formalin-fixed, paraffin-embedded tissue slices. It combines microfluidic compartmentalization, in situ allele-specific PCR, and fluorescence microscopy. The experimental proof of principle was achieved by in situ detection of KRAS G12V mutation in colorectal cancer tissues and is presented herein. HistoMosaic offers the ability to detect mutations over the entire tissue slide simultaneously, rapidly, economically, and without selection bias, while coregistering the genetic information with the preserved morphological information. Thus, HistoMosaic has wide applicability in basic science as a tool to map genetic heterogeneity. It is also a platform to build companion diagnostics for targeted therapies in oncology, to help ensure that the right drug is given to the right patient, thereby saving healthcare resources and improving patient outcomes.
登录
查看更多内容
影响因子：
48
作者：
Raj, Arjun;van den Bogaard, Patrick;Rifkin, Scott A.;van Oudenaarden, Alexander;Tyagi, Sanjay
通讯作者：
Tyagi, Sanjay
影响因子：
7.5
作者：
Boissiere-Michot, Florence;Lopez-Crapez, Evelyne;Bibeau, Frederic
通讯作者：
Bibeau, Frederic
影响因子：
64.8
作者：
Sawyers, C
通讯作者：
Sawyers, C
影响因子：
9.3
作者：
Azuara, Daniel;Ginesta, Mireia M.;Capella, Gabriel
通讯作者：
Capella, Gabriel
影响因子：
3.7
作者：
Schleifman, Erica B.;Tam, Rachel;Raja, Rajiv
通讯作者：
Raja, Rajiv